Suppr超能文献

体力活动与非酒精性脂肪性肝病:美国运动医学学会圆桌会议声明。

Physical Activity and Nonalcoholic Fatty Liver Disease: A Roundtable Statement from the American College of Sports Medicine.

机构信息

Section of Gastroenterology, Evans Department of Medicine, Boston University School of Medicine, Boston, MA.

Division of Gastroenterology and Hepatology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

出版信息

Med Sci Sports Exerc. 2023 Sep 1;55(9):1717-1726. doi: 10.1249/MSS.0000000000003199.

Abstract

Although physical activity (PA) is crucial in the prevention and clinical management of nonalcoholic fatty liver disease, most individuals with this chronic disease are inactive and do not achieve recommended amounts of PA. There is a robust and consistent body of evidence highlighting the benefit of participating in regular PA, including a reduction in liver fat and improvement in body composition, cardiorespiratory fitness, vascular biology, and health-related quality of life. Importantly, the benefits of regular PA can be seen without clinically significant weight loss. At least 150 min of moderate or 75 min of vigorous intensity PA are recommended weekly for all patients with nonalcoholic fatty liver disease, including those with compensated cirrhosis. If a formal exercise training program is prescribed, aerobic exercise with the addition of resistance training is preferred. In this roundtable document, the benefits of PA are discussed, along with recommendations for 1) PA assessment and screening; 2) how best to advise, counsel, and prescribe regular PA; and 3) when to refer to an exercise specialist.

摘要

尽管身体活动(PA)对非酒精性脂肪性肝病的预防和临床管理至关重要,但大多数患有这种慢性疾病的个体都不活跃,无法达到推荐的 PA 量。有大量确凿的证据强调了定期参加身体活动的益处,包括减少肝脏脂肪和改善身体成分、心肺健康、血管生物学以及健康相关的生活质量。重要的是,定期进行身体活动即使没有明显的体重减轻也可以带来益处。建议所有非酒精性脂肪性肝病患者(包括代偿性肝硬化患者)每周进行至少 150 分钟的中等强度或 75 分钟的剧烈强度身体活动。如果规定了正式的运动训练计划,则首选有氧运动加抗阻训练。在这份圆桌文件中,讨论了 PA 的益处,并就以下方面提出了建议:1)PA 评估和筛查;2)如何最好地提供建议、咨询和开具定期 PA 的处方;以及 3)何时转介给运动专家。

相似文献

1
Physical Activity and Nonalcoholic Fatty Liver Disease: A Roundtable Statement from the American College of Sports Medicine.
Med Sci Sports Exerc. 2023 Sep 1;55(9):1717-1726. doi: 10.1249/MSS.0000000000003199.
4
Physical activity support or weight loss counseling for nonalcoholic fatty liver disease?
World J Gastroenterol. 2014 Aug 7;20(29):10128-36. doi: 10.3748/wjg.v20.i29.10128.

引用本文的文献

1
Co-designing Approaches to Sustainable Exercise Care for People with Metabolic Dysfunction-associated Steatotic Liver Disease.
J Clin Transl Hepatol. 2025 Sep 28;13(9):707-722. doi: 10.14218/JCTH.2025.00155. Epub 2025 Aug 21.
3
Exploring the Impact of Physical Activity on Cryptogenic Steatotic Liver Disease: A Nigerian Case-Control Study.
Niger Med J. 2025 Jun 16;66(2):754-760. doi: 10.71480/nmj.v66i2.794. eCollection 2025 Mar-Apr.
4
Guts for Self-Eating: Role of Autophagy in Gastrointestinal Health and Disease.
Gastro Hep Adv. 2025 Mar 15;4(6):100654. doi: 10.1016/j.gastha.2025.100654. eCollection 2025.
6
Aerobic exercise interventions lead to MASH resolution in clinical trials: Pooled analysis using the MASH resolution index.
Hepatol Commun. 2025 Mar 24;9(4). doi: 10.1097/HC9.0000000000000681. eCollection 2025 Apr 1.
8
Multidisciplinary clinic model enhances liver and metabolic health outcomes in adults with MASH.
Hepatol Commun. 2025 Feb 3;9(2). doi: 10.1097/HC9.0000000000000649. eCollection 2025 Feb 1.
9
Systematic review of exercise for the treatment of pediatric metabolic dysfunction-associated steatotic liver disease.
PLoS One. 2024 Dec 10;19(12):e0314542. doi: 10.1371/journal.pone.0314542. eCollection 2024.
10
The impact of resistance training in patients diagnosed with metabolic dysfunction-associated steatotic liver disease: a systematic review.
Eur J Gastroenterol Hepatol. 2025 Feb 1;37(2):129-136. doi: 10.1097/MEG.0000000000002887. Epub 2024 Nov 19.

本文引用的文献

2
Mobile health lifestyle intervention program leads to clinically significant loss of body weight in patients with NASH.
Hepatol Commun. 2023 Mar 17;7(4). doi: 10.1097/HC9.0000000000000052. eCollection 2023 Apr 1.
3
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
5
Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness.
Dig Dis Sci. 2023 Jun;68(6):2695-2703. doi: 10.1007/s10620-022-07809-w. Epub 2023 Jan 24.
6
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
8
Physical Activity and Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Dig Dis Sci. 2023 Mar;68(3):1051-1059. doi: 10.1007/s10620-022-07601-w. Epub 2022 Jun 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验